MTOR and interstitial lung disease: Several anti-HER2 therapies, as well as other anticancer agents (e.g., cyclin-dependent kinase-4/-6 inhibitors, immune checkpoint inhibitors, mammalian target of rapamycin [mTOR] inhibitors), have been linked to an increased risk of drug-induced interstitial lung disease (ILD) [3, 4, 7–10].